[Clinical pharmacology of two new oral antidiabetics of the sulfonamide type (author's transl)].
Pharmacodynamic studies were performed with two new blood glucose lowering sulfonamides of high potency: gliquidone and gliflumide. The aim was to obtain equipotent doses on the basis of a maximum 30% blood glucose decrease in healthy normals (Ed 30) in order to compare the new compounds with the well known effects of tolbutamide and glibenclamide. Our investigations demonstrated a dose dependent blood glucose decrease with each sulfonylurea corresponding with the insulin levels after intravenous application. Gliquidone revealed a "tolbutamide-typed" dynamic both on insulin secretion and on blood glucose decrease whereas gliflumide showed a "glibenclamide-typed" reaction. The delayed and more prolonged insulin decrease, well known for glibenclamide, was even more distinct following gliflumide. Differences of insulin secretion after sulfonulureas can be observed only under intravenous conditions. Following oral application an only small increase of insulin can be noted when measured in peripheral blood.
D000284:Administration, Oral; D001786:Blood Glucose / Q000032:analysis; D001835:Body Weight; D006801:Humans; D007004:Hypoglycemic Agents; D007275:Injections, Intravenous; D007328:Insulin / Q000097:blood; D013453:Sulfonylurea Compounds / Q000008:administration & dosage / Q000494:pharmacology*
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D013453:Sulfonylurea Compounds
Zur Pharmakodynamik von zwei neuen Sulfonylharnstoffderivaten.